Agenda for August 2026 Pharmacology and Therapeutics Advisory Committee (PTAC) meeting

Applications

Canakinumab (branded as Ilaris) for people with Still’s disease

The Committee will discuss the use of canakinumab, a treatment for people living with Still’s disease as a first line biologic treatment. Still’s disease is a rare autoinflammatory condition that presents with symptoms including fever, rash, joint pain and swelling, and multi-system inflammation.

Application for Canakinumab(external link)

Inclisiran (branded as Leqvio) for people with atherosclerotic cardiovascular disease (ASCVD)

The Committee will discuss the use of inclisiran, a treatment for people living with atherosclerotic cardiovascular disease (ASCVD) who are at high risk. ASCVD is a chronic condition that can lead to serious cardiovascular events such as heart attack and stroke. Inclisiran would be used in addition to diet, exercise, statin and/or ezetimibe therapy.

Application for Inclisiran for ASCVD(external link)

Faricimab (branded as Vabysmo) for people with macular oedema, secondary to retinal vein occlusion

The Committee will discuss the use of faricimab a treatment for people living with macular oedema secondary to retinal vein occlusion. This condition occurs when a blockage in the retinal vein leads to fluid accumulation in the macula, resulting in vision impairment. Faricimab will be considered as a second line anti-VEGF agent.

Application for Faricimab for macular oedema due to retinal vein occlusion(external link)

Elemental Food (Elemental Gold) for currently funded uses

The Committee will discuss the use of elemental food (Elemental Gold and Elemental Gold plus) for people with conditions requiring specialised nutritional support. These products will be considered as an alternative to other current funded nutritional products for the same uses.

Application for Elemental Food(external link)

Advisory meeting agenda setting

The scheduling and agenda setting process for advisory meetings considers multiple factors. We aim to balance the relative priorities of clinical advice needed across indications, the factors for consideration for each application (for example unmet health need), the time since applications were received and the internal and advisor resource available to support each meeting.